Licensing opportunities


IBEC is committed to knowledge and technology transfer to the biomedical sector.

Part of its mission is to collaborate closely with industry allies or to create spin offs in order to effectively translate its research know-how into technologies or products that can benefit society.

Elisabetta Ranucci, Paolo Ferruti, Fabio Fenili, Amedea Manfredi, Nicolò Mauro, Patricia Urbán, Xavier Fernández-Busquets UNIMI / CRESIB / IBEC / UPC (Invented by Joint unit IBEC-CRESIB)
Antimalarial drug delivery currently relies on the administration of soluble drugs with little or no specificity for the main target cell, namely the Plasmodium-infected red blood cell (pRBC). Due to this lack of specificity, current oral or intravenous delivery approaches for most antimalarial drugs require high doses. Drugs used for the treatment of malaria have side effects and inconvenient dosing schedules that limits the compliance of patients. Moreover resistance to many of the currently available antimalarial drugs is spreading rapidly, threatening people in areas where malaria is endemic.
The invention relates to the use of amphoteric polyamidoamines (PAAs) with high molecular weight as antimalarial agents and as carriers of antimalarial drugs in the treatment of malaria. The PAAs here invented have a significant antimalarial activity per se, low unspecific toxicity, high biodegradability, capability to target pRBC, capability -if conjugated to proteins- to specifically carry anti-malarial drugs into pRBC, and increased in vivo activity of some carried drugs (chloroquine). These compounds may be regarded as promising candidates deserving to enter into the antimalarial therapeutic arena.
Eduard Torrents, Fernando Albericio, Laia Miret IBEC / IRB
Antibiotics play a key role in today’s society. However, bacterial resistance to these drugs is becoming a public health concern, the most dangerous infections being those associated with biofilms.
The invention relates to the discovering of a family of hydroxylamines capable of arresting bacterial growth at relatively low concentrations. The compounds of the invention have been shown to have a minimum inhibitory concentration (MIC) against several bacteria (both Gram-positive and Gram-negative), which is substantially lower than the MICs of N-benzylhydroxylamine and other hydroxylamines of similar structure.
The novelty of these compounds is that they exert antibiotic activity even in the presence of bacterial biofilms, which occur in many chronic pulmonary infections such as cystic fibrosis and COPD. They also have valuable prophylactic applications on stents or other prosthetic implants. Activity has been tested in vitro against cultures of S. aureus, P. aeruginosa, B. anthracis, E. faecalis, B. cenocepacia, Mycoplasmas spp. and S. epidermidis, showing some MIC values around 100 μM (differing for the molecule and species tested).
Amadeo Llebaria Soldevilla, Jesús Giraldo Arjonilla, Xavier Rovira Algans, Xavier Gómez Santacana, Silvia Pittiolo, Pau Gorostiza Langa, Cyril Goudet, Xavier Rovira Algans, Jean Philippe Pin CSIC / UAB / ICREA / IBEC / CNRS
Drugs that target G protein-coupled receptors (GPCRs) account for the majority of best-selling medicines on the market and nearly half of the prescription pharmaceuticals. However, these drugs are applied systemically and it is not possible regulate their spatial effects in order to target to a specific organ of interest.
The invention relates to the development of the first light-regulated negative allosteric modulators (NAM) of the metabotropic glutamate receptor 5 (mGluR5) with potential pharmacological activity on important therapeutic targets. Administration of these light-regulated drugs in combination with light specifically in certain time and region would provide a qualitatively new degree of control and regulation of drug action.
Due to the roles of mGlu5 receptors in synaptic transmission, these light regulated compounds may have application for pain, Parkinson, epilepsy or anxiety treatments, with local controlled application.
High potency of these compounds has been proved both in vitro, in cultured HEK cells overexpressing mGluR5 and rat cortical astrocytes, showing an IC50 between 30-500 nM and in vivo in a Xenopus tropicalis tadpoles model.
Alicia Casals, Albert Hernansanz, Ramon Rovira IR-HSCSP / UPC / IBEC
The invention relates to a modular system for training and evaluation of laparoscopic surgery framed within a theoretical and practical training program. Main capabilities and advantages are: ability to record and evaluate the execution of the exercise, statistical analysis of the evolution of users, integration in a training course within the framework of the European Society (ESGE), customized training programme, use of augmented reality (education-operation mode), internet network integration and reduced need for a mentor. The system could avoid subjective evaluation methods, reduce educating costs in the operating room and increase learning curve of students to perform complex maneuvers. It has been already validated with surgeons, and new training modules in gynecology, general surgery and urology are being developed.
A method of joining scaffolds for tissue engineering implants and Transplant applications in surgery by means of layer-by layer method (DE 10 2014 017 950.8)
Thomas Groth, Deepak Guduru, George Altankov, Marcy Zenobi-Wong Martin Luther University – Halle-Wittenberg / IBEC / EIT Zurich
The invention relates to porous frameworks, fiber-made membranes or pressed structures, particles and hydrogels in a modular fashion to generate complex tissue network constructs that can be transferred to damaged or defective tissue and be assembled there, based on the coating of these moldings with polyelectrolyte multilayers which allows the binding within the neighboring tissue via chemical or biochemical processes.

Comments are closed